Physician profile
Fior Rojas
NPI 1114304508
$1,121.57
in general payments reported to CMS, 2019-2025
15 companies · $14.20 in 2025
The $14.20 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.10 · 2022: $589 · 2023: $296 · 2024: $152 · 2025: $14.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $461.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $234.81 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $175.14 | 2022-2023 | Qulipta |
| Glaxosmithkline, LLC. | $140.64 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.37 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $89.81 | 2022-2024 | Farxiga |
| Lilly USA, LLC | $84.17 | 2019-2023 | Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $68.33 | 2022-2023 | |
| Lundbeck LLC | $49.80 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $38.38 | 2022-2023 | |
| Pfizer INC. | $35.00 | 2022-2024 | |
| Amgen INC. | $32.81 | 2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $32.04 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $14.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.61 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fior Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.